Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series

Figure 1. Flow chart of the treatment response and overall outcomes. “+” indicates that follow-up was conducted under close surveillance, as of the data cutoff on April 15, 2025.

Figure 2. Waterfall plot of maximum tumor reduction outcomes in individual patients with ASPS or UPS. The waterfall plot was constructed, displaying the percentage change from the baseline tumor size, with the ASPS patients represented by blue bars and the UPS patients by red bars. Cases are arranged from left to right by a decreasing magnitude of tumor shrinkage. The upper black dotted horizontal line is set at +20%, indicating that tumor growth exceeding 20% corresponds to a PD assessment. The lower black dotted horizontal line is set at −30%, indicating that tumor shrinkage greater than 30% corresponds to an assessment of a PR or even a CR.

Figure 3. Spider plot of the percentage change of tumor size from baseline at each tumor response assessment. The spider plot was created, illustrating tumor reduction from baseline and variations in the treatment response.

Figure 4. Swimmer plot depicting the treatment duration and follow-up for each patient. Horizontal bars represent individual patients, with colored segments denoting the treatment duration (light-red segments) and follow-up period (green segments).

Figure 5. Kaplan–Meier curve of PFS by histologic subtypes (ASPS vs. UPS, not reached vs. 7.5 months). No statistical comparisons were performed between groups due to the small sample size.

Figure 6. Kaplan–Meier curve of OS by histologic subtypes (ASPS vs. UPS, not reached vs. 9.5 months). No statistical comparisons were performed between groups due to the small sample size.

Figure 7. Kaplan–Meier curve analysis of the difference in PFS between prior first-line and non-first-line therapies in the ASPS subgroup.

Figure 8. Kaplan–Meier curve analysis of the difference in OS between prior first-line and non-first-line therapies in the ASPS subgroup.